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Abstract 
Background: Hyperglycemia is acknowledged as a pro‑inflammatory condition and a major cause of vascular dam‑
age. Nevertheless, we have previously described that high glucose only promotes inflammation in human vascular 
cells previously primed with pro‑inflammatory stimuli, such as the cytokine interleukin (IL)1β. Here, we aimed to iden‑
tify the cellular mechanisms by which high glucose exacerbates the vascular inflammation induced by IL1β.
Methods: Cultured human aortic smooth muscle cells (HASMC) and isolated rat mesenteric microvessels were 
treated with IL1β in medium containing 5.5–22 mmol/L glucose. Glucose uptake and consumption, lactate produc‑
tion, GLUT1 levels, NADPH oxidase activity and inflammatory signalling (nuclear factor‑κB activation and inducible 
nitric oxide synthase expression) were measured in HASMC, while endothelium‑dependent relaxations to acetylcho‑
line were determined in rat microvessels. Pharmacological inhibition of IL1 receptors, NADPH oxidase and glucose‑
6‑phosphate dehydrogenase (G6PD), as well as silencing of G6PD, were also performed. Moreover, the pentose 
phosphate pathway (PPP) activity and the levels of reduced glutathione were determined.
Results: We found that excess glucose uptake in HASMC cultured in 22 mM glucose only occurred following activa‑
tion with IL1β. However, the simple entry of glucose was not enough to be deleterious since over‑expression of the 
glucose transporter GLUT1 or increased glucose uptake following inhibition of mitochondrial respiration by sodium 
azide was not sufficient to trigger inflammatory mechanisms. In fact, besides allowing glucose entry, IL1β activated 
the PPP, thus permitting some of the excess glucose to be metabolized via this route. This in turn led to an over‑
activation NADPH oxidase, resulting in increased generation of free radicals and the subsequent downstream pro‑
inflammatory signalling. Moreover, in rat mesenteric microvessels high glucose incubation enhanced the endothelial 
dysfunction induced by IL1β by a mechanism which was abrogated by the inhibition of the PPP.
Conclusions: A pro‑inflammatory stimulus like IL1β transforms excess glucose into a vascular deleterious agent by 
causing an increase in glucose uptake and its subsequent diversion into the PPP, promoting the pro‑oxidant condi‑
tions required for the exacerbation of pro‑oxidant and pro‑inflammatory pathways. We propose that over‑activation 
of the PPP is a crucial mechanism for the vascular damage associated to hyperglycemia.
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Background
At present, hyperglycaemia is recognized as an inde-
pendent risk factor for cardiovascular disease. Thus, it 
has been proposed that high glucose per se induces oxi-
dative stress that results in vascular damage, due to an 
excess entry of glucose into the cell leading to the over-
production of superoxide anions in the mitochondria [1]. 
However, clinical trials have shown that strict control of 
glycaemia leads only to a modest reduction in macrovas-
cular diabetic complications [2]. Thus, the link between 
hyperglycaemia and atherosclerosis is still not fully 
understood [3], while the role for mitochondrial superox-
ide as the culprit of diabetes complications is now ques-
tioned [4, 5].
We have previously shown that exposure to high con-
centrations of glucose does not cause inflammation in 
human vascular cells unless the cells are primed with 
an inflammatory stimulus such as interleukin (IL)1β 
or tumour necrosis factor (TNF)α [6, 7]. This led us to 
conclude that a background inflammatory condition 
is necessary for the elevation of extracellular glucose 
to become deleterious in the vasculature, which can 
explain why glycaemic control alone is not sufficient 
to avoid diabetic vascular damage. Understanding the 
mechanisms by which an inflammatory environment 
transforms high glucose into a deleterious agent can 
provide new therapeutic targets for preventing diabetic 
complications.
In the present work, we have explored in human vascu-
lar smooth muscle cells the role of the pro-inflammatory 
cytokine IL1β on the uptake and utilization of glucose 
and the possible mechanisms linking glucose metabolism 
with pro-inflammatory signalling. Furthermore, using 
rat mesenteric microvessels, we investigated whether 
how endothelial dysfunction induced by IL1β is potenti-
ated by high glucose concentrations. We propose that an 
excess of glucose entry is diverted through the pentose 
phosphate pathway (PPP), providing additional substrate 
for the enzyme NADPH oxidase and results in a pro-oxi-
dant environment that exacerbates inflammation.
Methods
Ethical approval
The Ethics Committees for Clinical Research from 
Hospital Universitario de Getafe (reference numbers 
11-20 and 14-117) and Hospital Universitario La Paz 
(reference numbers PI-1111 and PI-1878) approved 
the protocol in human cell cultures. The studies on ani-
mals were performed according to national and Euro-
pean guidelines (2010/63/EU), approved by the ethics 
committee of Universidad Autónoma de Madrid (CEI 
27-670), and developed in registered animal facilities 
(ES-28079-000097).
Cell culture
Human aortic smooth muscle cells (HASMC) were 
obtained by enzymatic dissociation from the aortae of 
five organ donors, who had no evidences for cardiomet-
abolic diseases or risk factors, and according to Spanish 
legal regulations as previously described [6]. The cells 
were routinely cultured in Dulbecco’s Modified Eagle 
Medium (DMEM, Biological Industries, Beit-Hamek, 
Israel) supplemented with 10  % fetal calf serum (FCS, 
Biological Industries), 100  µg/ml streptomycin (Reig-
Jofré, Barcelona, Spain), 100  U/ml penicillin (ERN SA, 
Barcelona, Spain) and 2.5 µg/ml amphotericin B (Sigma 
Chemical Co., St. Louis, MO, USA). At confluence, the 
cells were passaged using a 0.02 % EDTA-0.05 % trypsin 
solution (Biological Industries). The cells were counted 
using a hemocytometer. Cell characterization was car-
ried out based on both cell morphology and indirect 
immunofluorescence staining of α-smooth muscle actin. 
For experiments, confluent cells were serum-deprived 
for 24  h prior to the addition of the different test com-
pounds in serum-free DMEM supplemented with 0.1 % 
bovine serum albumin (BSA, Sigma). Confluent cultures 
between passages 3 and 12 were used.
Glucose consumption and lactate production
The cells were plated onto 48-well plates at a density of 
20,000 cells per well. After serum-deprivation the cells 
were incubated for 24 h in DMEM with 0.1 % BSA and 
different initial concentrations of glucose (5.5, 11, or 
22 mmol/L); in some experiments, the cultures were also 
treated with 1–10  ng/mL interleukin-1β (IL1β; Pepro-
tech, London, UK) or 0.5 mmo/L sodium azide (Sigma). 
Glucose consumption and lactate release over 8 or 24 h 
of incubation were determined by measuring the respec-
tive levels in the culture medium at time 0 and after 8 
or 24  h using commercial kits (Glucose HK Assay kit, 
Sigma; Lactate Reagent kit, Trinity Biotech, Wicklow, Ire-
land). Glucose consumption was calculated as the differ-
ence between initial and final glucose levels, while lactate 
production was calculated as the difference between final 
and initial lactate levels. Results were normalized by cell 
number. Both glucose consumption and lactate produc-
tion were expressed as pmol per cell over 8 or 24 h.
Cytochalasin B‑sensitive 3H‑deoxyglucose uptake
Cytochalasin B-sensitive 3H-deoxyglucose uptake was 
used as an indicator of the cellular GLUT1 transporter 
capacity. Briefly, cells were incubated for 18 h in 24-well 
plates containing DMEM with 0.1  % BSA and 5.5 or 
22 mmol/L glucose; in some experiments, the cells were 
also treated with 1–10  ng/mL IL1β 1  ng/mL anakinra 
(Biovitrum, SOBI, Stockholm, Sweden), or 0.5  mmol/L 
sodium azide. The 18  h optimal period for such 
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treatments was established in preliminary experiments 
(data not shown). After washing in a Krebs–Ringer solu-
tion free of glucose (KRS; composition in mmol/L, NaCl 
136, KCl 4.7, MgSO4 1.25, CaCl2 1.25, pH 7.4 HEPES 10), 
the cultures were pre-incubated for 15 min in KRS with-
out d-glucose, in the presence or absence of the GLUT1 
transporter blocker cytochalasin B (Sigma; 20  µmol/L). 
The cultures were then incubated for 5  min in KRS 
without cold d-glucose containing 1  µCi/mL 3H-deoxy-
glucose (activity 8.00 Ci mmol; Amersham, Buckingham-
shire, UK), in the absence or presence of cytochalasin B. 
The optimal 5 min time for such incubation period was 
established in preliminary experiments (data not shown). 
After washing with KRS, the protein content was deter-
mined by the bicinchoninic acid (BCA) assay and the 
radioactivity incorporated to the cells was measured in 
a liquid scintillation counter (Tri-Carb 2800 TR, Perkin 
Elmer, Waltham, MA, USA). Results were expressed in 
dpm/µg protein.
GLUT1 lentiviral infection
A pCB6 plasmid containing the human GLUT1 cDNA 
sequence was a kind gift from Prof. David James (Garvan 
Institute of Medical Research, Darlinghurst Sydney NSW, 
Australia). The GLUT1 cDNA was subcloned into a len-
tiviral vector (pCDH-CMV-MCS-EF1-Puro, System Bio-
sciences SBI) using the XbaI restriction site. All plasmids 
were confirmed by PCR screening and DNA sequencing. 
Viral particles were generated according to the manufac-
turer’s protocol (pPACKH1 Lentivector Packaging Kit, 
SBI, Mountain View, CA, USA). The cells were infected 
with viral particles (GLUT1+) in the presence of 4  µg/
mL polybrene (Sigma) and selected in 1 µg/mL puromy-
cin (Sigma) for 3 days. Matched cells subjected to infec-
tion with empty vector lentiviral plasmids (EV) were used 
as controls.
Rt‑pcr
For GLUT1 mRNA quantification, total RNA was 
extracted from vascular cells after 18  h of treatment 
using a commercial kit (RNeasy, Qiagen; Crawley, UK) 
and quantified by absorbance at 260  nm. Aliquots of 
1  µg RNA were reverse-transcribed using Moloney 
murine leukemia virus-reverse transcriptase (Sigma). The 
resulting cDNA was amplified using a human GLUT1 
gene-specific relative RT-PCR kit (Ambion, Austin, TX, 
USA) containing an 18S internal standard, according to 
the manufacturer’s instructions. The reaction was con-
ducted in a Peltier PTC100 thermocycler (M&J Research, 
Waltham, MA, USA) with an initial denaturation step at 
95 °C for 3 min, followed by 23 cycles each consisting of 
incubation at 94 °C for 30 s, 59 °C for 30 s, and 72 °C for 
30  s. Aliquots of the resulting PCR were loaded on 2 % 
agarose gels containing ethidium bromide, the resulting 
bands were visualized under ultraviolet light and quanti-
fied using NIH Image free software.
Indirect immunofluorescence
As previously described [6, 7], cells grown on glass cov-
erslips were exposed for 18 h to the different treatments, 
fixed with acetone at −20 °C and blocked in a PBS solu-
tion containing 1 % BSA and 0.1 % Triton X-100. The cells 
were then incubated with a primary polyclonal antibody 
against GLUT1 (dilution 1/50; Neomarkers, Fremont, 
CA, USA), followed by incubation with an appropri-
ate Alexa Fluor 488-secondary antibody (dilution 1/200; 
Molecular Probes-Invitrogen Corporation). Nuclei 
were counterstained with 4′,6-diamino-2-phenylindole 
(DAPI). Cells were observed with an Eclipse TE300 epi-
fluorescence microscope (Nikon, Tokyo, Japan) and a 
spectral confocal microscope (Leica TCSSP5-AOBS, 
Leica microsystems, Heidelberg, GMBH, Germany). 
Confocal images were analyzed with LAS AF software, 
version 1.5.1 Build 869 (Leica).
Western blotting
After washing with PBS, the cells were subjected to 
extraction in lysis buffer containing 10  mmol/L Tris 
pH 7.4, 1  % sodium dodecyl sulfate (SDS), 10  mmol/L 
sodium orthovanadate, 2  mmol/L phenylmethylsulfo-
nyl fluoride and 12.5  µg/mL aprotinin (all from Sigma). 
Proteins (20 µg per lane) were equally loaded and sepa-
rated on 8 % SDS-PAGE and transferred onto a nitrocel-
lulose membrane (BioRad Laboratories, Madrid, Spain). 
After blocking overnight, the membrane was incubated 
for 1  h at room temperature with polyclonal antibodies 
against iNOS (dilution 1/10,000; Transduction Labo-
ratories, Lexington, KY, USA) or glucose-6-phosphate 
dehydrogenase (G6PD, dilution 1/5000, Sigma), followed 
by incubation for 1 h with a horseradish peroxidase-con-
jugated secondary antibody (dilution 1/10,000; Chemi-
con, Temecula, CA, USA), as described previously [6]. 
Immunoreactive bands were detected using an enhanced 
chemiluminescence detection kit (GE Healthcare, Upp-
sala, Sweden) and quantified by densitometry using NIH 
Image software. The membranes were stripped and rep-
robed with an anti α-tubulin primary antibody (dilution 
1/10,000; Sigma) to ensure equal loading.
Nuclear extracts and electrophoretic mobility shift assay 
(EMSA)
After 18  h of treatment, nuclear extracts from cell cul-
tures were prepared as previously described [6, 7]. For 
binding reactions, nuclear extracts (5 μg) were incubated 
on ice for 15 min in a reaction buffer (pH 7.0 40 mmol/L 
HEPES, 140  mmol/L NaCl, 5  mmol/L dithiothreitol, 
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10  μg/mL BSA, 0.01  % Nonidet P-40, 4  % Ficoll and 
0.05  μg/mL poly [dI-dC]poly [dI-dC]). A commercial 
oligonucleotide (Promega, Madison, WI, USA) encod-
ing the NF-κB consensus sequence (5′-AGTTGAGGGG 
ACTTTCCCAGGC-3′) and 5′ end-labelled with ©-32P 
(~50,000  cpm) was then added, and the reaction mix 
incubated for 20  min at room temperature. DNA–pro-
tein complexes were resolved on 4 % nondenaturing pol-
yacrylamide gels in 0.5 × TBE (45 mmol/L Tris–borate, 
1  mmol/L EDTA, pH 8.0) at 4  °C. Gels were dried and 
exposed for autoradiography at −80 °C.
Measurement of the pentose phosphate pathway (PPP) 
flux
Carbon flux from glucose through the PPP was measured 
in cells treated for 120 min, as previously described [8], 
with minor modifications. Briefly, suspensions of known 
amounts of cells (3–5  ×  105 cells) obtained by smooth 
detaching from the cultures were incubated in sealed 
vials containing a central well with KOH (4 mol), which 
was used for 14CO2 trapping, in the presence of 0.5 μCi 
of D-[1-14C]glucose (activity 56  mCi/mmol/L; Per-
kin Elmer) or D-[6-14C]glucose (activity 60 mCI/mmol/L; 
Perkin  Elmer) in a Krebs–Ringer phosphate buffer 
(5.7 mmol/L Na2HPO4, 145 mmol/L NaCl, 4.86 mmol/L 
KCl, 1.22  mmol/L MgSO4, 0.54  mmol/L CaCl2; pH 7.4) 
containing 5.5 or 22 mmol/L glucose at 37 °C. In order to 
ensure an adequate O2 supply for oxidative metabolism 
by the cells throughout the 120  min incubation period, 
the gas phase in the vials containing the cells was sup-
plied with extra O2 before the vials were sealed. The PPP 
flux was measured by assessing the difference between 
14CO2 production from [1-14C]glucose—which decar-
boxylates via the 6-phosphogluconate dehydrogenase-
catalyzed reaction and the tricarboxylic acid cycle—and 
that of [6-14C]glucose—which decarboxylates only via the 
tricarboxylic acid cycle [8, 9].
NADPH oxidase activity
NADPH oxidase activity was measured by lucigenin-
derived chemiluminescence, as described previously 
[10]. After the various treatments described, the cells 
were washed in ice-cold PBS, scraped and centrifuged 
at 13,000  rpm for 1  min at 4  °C. The resulting cell pel-
let was homogenized in lysis buffer (pH 7.0) containing 
50 mmol/L KH2PO4, 1 mmol/L EGTA and 150 mmol/L 
sucrose for 5  min at 4º C. The activity of NADPH oxi-
dase was measured by lucigenin-derived chemilumines-
cence. For oxidase assay, cells samples (5 µg protein) were 
incubated in PBS containing 5  µmol/L lucigenin and 
100 µmol/L NADPH. Luminiscence was measured every 
30 s for 5 min in a tube luminometer (Optocomp, MGM 
Instruments, Hamden, CT, USA). The enzymatic activity 
was obtained as relative light units (RLU)/µg protein 
min−1 determined by the BCA method.
Determination of total glutathione and GSH
After 24  h of serum deprivation, cells were incubated 
for a further 18  h period, with the different treatments 
in serum-free medium. After the treatment described, 
the cells were washed in ice-cold PBS, scraped and cen-
trifuged at 1200 rpm for 8 min at 4 °C. Total glutathione 
and GSH were determined in the resulting pellet using a 
commercial kit (Glutathione Colorimetric Detection kit, 
Arbor Assays, Ann Arbor, MI, USA).
siRNA transfection
G6PD silencing was achieved by a procedure previ-
ously described [11]. For silencing, the On-TARGETplus 
SMARTpool for human G6PD siRNA (Dharmacon, Upp-
sala, Sweden) was used, according to manufacturer’s 
instructions. The On-Targetplus Non-targeting siRNA #1 
(Dharmacon) was used as a negative control. Afterwards, 
cells were serum-deprived for 24 h and then submitted to 
the appropriate treatments for Western blot or NADPH 
oxidase activity determination, as described above.
Reactivity studies in rat mesenteric microvessels
Isolated mesenteric microvessels from 16-week male 
old Sprague–Dawley (SD) rats (300–350 g) were studied 
ex vivo. The animals were briefly exposed to a chamber 
filled with carbon dioxide until they fell unconscious and 
then immediately killed by cervical dislocation. The mes-
entery was removed, and placed in a Petri dish containing 
Krebs-Henseleit solution (KHS) at 4 °C. The third branch 
mesenteric arteries were dissected (mean internal diam-
eter ranged between 200 and 400  µm; non-significant 
differences were observed among the different groups 
of rats). The arteries were dissected and cleaned free of 
fat and connective tissue under a light microscope and 
mounted as ring preparations on a small vessel myo-
graph [12] to measure isometric tension. Arteries were 
bathed in KHS at 37 °C continuously bubbled with a 95 % 
O2-5 % CO2 mixture, which yields a pH of 7.4 and their 
passive tension and internal circumference were deter-
mined. The arteries were subjected to optimal tension 
(90 % of the tension equivalent to a intramural pressure 
of 100 mm Hg. After 30 min of equilibration, the vessels 
were exposed to 125  mmol/L KCL (KKHS, equimolar 
substitution of KCl for NaCl in KHS) for 2 min in order 
to check their functional integrity. Segments failing to 
achieve a maximum active tension equivalent to a pres-
sure of 100 mmHg were rejected [12].
The bath was then washed three times with KHS and 
a further period of 180 min washout period was allowed 
with KHS containing 5.5 or 22  mmol/L glucose before 
Page 5 of 15Peiró et al. Cardiovasc Diabetol  (2016) 15:82 
Ta
bl
e 
1 
G
lu
co
se
 c
on
su
m
pt
io
n 
an
d 
la
ct
at
e 
re
le
as
e 
ov
er
 2
4 
h,
 a
nd
 ra
ti
o 
be
tw
ee
n 
la
ct
at
e 
pr
od
uc
ti
on
 a
nd
 g
lu
co
se
 c
on
su
m
pt
io
n 
in
 h
um
an
 v
as
cu
la
r s
m
oo
th
 m
us
cl
e 
ce
lls
 in
 c
ul
tu
re
Re
su
lts
 a
re
 e
xp
re
ss
ed
 a
s 
th
e 
m
ea
n 
± 
st
an
da
rd
 e
rr
or
 o
f 5
–2
8 
se
pa
ra
te
 e
xp
er
im
en
ts
EV
 c
el
ls
 w
ith
 a
 le
nt
iv
ira
l e
m
pt
y 
ve
ct
or
, G
LU
T1
+ 
ce
lls
 w
ith
 a
 le
nt
iv
ira
l v
ec
to
r c
on
ta
in
in
g 
hu
m
an
 G
LU
T1
 c
D
N
A
*P
 <
 0
.0
5 
vs
 th
e 
re
sp
ec
tiv
e 
co
nt
ro
l. 
† P
 <
 0
.0
5 
vs
 th
e 
re
sp
ec
tiv
e 
va
lu
e 
in
 5
.5
 m
m
ol
/L
 g
lu
co
se
(a
) C
on
tr
ol
Ba
sa
l
10
 n
g/
m
L 
IL
‑1
β
0.
5 
m
m
ol
/L
 s
od
iu
m
 a
zi
de
In
iti
al
 e
xt
ra
ce
llu
la
r  
gl
uc
os
e 
(m
m
ol
/L
)
G
lu
co
se
  
co
ns
um
pt
io
n 
(p
m
ol
 p
er
 c
el
l)
La
ct
at
e 
 
pr
od
uc
tio
n 
(p
m
ol
 p
er
 c
el
l)
La
ct
at
e:
 
gl
uc
os
e 
ra
tio
G
lu
co
se
  
co
ns
um
pt
io
n 
(p
m
ol
 p
er
 c
el
l)
La
ct
at
e 
 
pr
od
uc
tio
n 
(p
m
ol
 p
er
 c
el
l)
La
ct
at
e:
 
gl
uc
os
e 
ra
tio
G
lu
co
se
  
co
ns
um
pt
io
n 
(p
m
ol
 p
er
 c
el
l)
La
ct
at
e 
 
pr
od
uc
tio
n 
 
(p
m
ol
 p
er
 c
el
l)
La
ct
at
e:
 
gl
uc
os
e 
ra
tio
5.
5
5.
3 
± 
0.
3
7.
0 
± 
0.
6
1.
3 
± 
0.
1
6.
0 
± 
0.
3*
7.
1 
± 
0.
6
1.
2 
± 
0.
1
6.
9 
± 
0.
1*
8.
8 
± 
0.
9
1.
3 
± 
0.
1
11
4.
9 
± 
0.
6
6.
4 
± 
1.
2
1.
3 
± 
0.
2
8.
1 
± 
0.
9*
†
9.
7 
± 
1.
7†
1.
2 
± 
0.
1
22
5.
5 
± 
0.
5
7.
6 
± 
0.
8
1.
4 
± 
0.
1
10
.0
 ±
 0
.9
*†
13
.0
 ±
 1
.6
*†
1.
3 
± 
0.
1
13
.2
 ±
 0
.8
*†
17
.7
 ±
 2
.2
*†
1.
4 
± 
0.
2
(b
) E
V 
an
d 
G
LU
T1
+
In
iti
al
 e
xt
ra
ce
llu
la
r g
lu
co
se
 (m
m
ol
/L
)
G
lu
co
se
 c
on
su
m
pt
io
n
La
ct
at
e 
pr
od
uc
tio
n
La
ct
at
e:
gl
uc
os
e 
ra
tio
EV
G
LU
T1
+
EV
G
LU
T1
+
EV
G
LU
T1
+
5.
5
6.
5 
± 
0.
7
6.
0 
± 
0.
1
7.
9 
± 
0.
4
6.
7 
± 
0.
5
1.
2 
± 
0.
1
1.
1 
± 
0.
1
22
6.
5 
± 
0.
4
6.
2 
± 
0.
2
9.
3 
± 
1.
0
8.
6 
± 
0.
3
1.
5 
± 
0.
1
1.
4 
± 
0.
2
Page 6 of 15Peiró et al. Cardiovasc Diabetol  (2016) 15:82 
the arteries were contracted with the concentration of 
NA (1  µmol/L) required to produce approximately 80  % 
of the maximum response to KKHS. Relaxations to ace-
tylcholine (ACh) were subsequently assessed by adding 
cumulative concentrations of the drug at 2  min inter-
vals (final bath concentrations 0.1  nmol/L–10  µmol/L). 
Some microvessels were pre-incubated with 2.5  ng/mL 
IL1β for 120  min before and during the administration 
of NA and ACh. Other vascular segments were treated 
with 2  mmol/L 6-aminonicotinamide or 10  µmol/L 
apocynin for 30 min in advance and during the adminis-
tration of IL1β, NA, and ACh. The composition of KHS 
(mmol/L) was NaCl 115, CaCl2 2.5, KCl 4.6, KH2PO4 1.2, 
MgSO4.7H2O 1.2, NaHCO3 25, glucose 5.5 or 22, and 
Na2EDTA 0.03.
Materials
Culture plasticware was obtained from TPP (Tragadin-
gen, Switzerland). All the reagents and drugs were pur-
chased from Sigma unless otherwise stated.
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mean ± standard error of 13–15 separate experiments. *P < 0.05 vs the respective control (c). b GLUT1 levels, determined by Western blot, in cells 
exposed for 18 h to IL1β (10 ng/mL) in medium initially containing 5.5 or 22 mmol/L glucose. The gels and blots shown are representative of 4–5 
separate experiments. Data are expressed as percentage of the basal expression in cells in medium initially containing 5.5 mmol/L glucose *P < 0.05 
vs the respective control (c). c Cytokine‑induced consumption of glucose in cells exposed for 24 to different concentrations of IL1β (1–10 ng/mL). 
Data were calculated by subtracting at every point the basal consumption of glucose. Results are expressed as mean ± standard error of 8–11 
separate experiments. *P < 0.05 vs 5.5 mmol/L glucose. †P < 0.05 vs 11 mmol/L glucose. d Uptake of 3H‑deoxyglucose by cells previously treated for 
18 h with different concentrations of IL1β (1–10 ng/mL) in medium containing 5.5 mmol/L glucose in the presence or absence of the glucose trans‑
porter inhibitor cytochalasin B (20 µmol/L). Results are the mean ± standard error of 3 separate experiments. *P < 0.05 vs cytochalasin B‑treated 
cells
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Statistical analysis
Results are expressed as mean ± standard error of at least 
three separate experiments. Statistical analysis was per-
formed using one-way or two-way ANOVA and Bonfer-
roni correction for multiple comparisons, with the level 
of significance selected as P < 0.05.
Results
IL1β enhances glucose transport capacity 
and consumption
At a physiological concentration of 5.5 mmol/L glucose, 
the cells consumed 2.1 ± 0.3 and 5.3 ± 0.3 pmol per cell 
during 8 and 24  h, respectively, exhibiting a predomi-
nantly glycolytic metabolism, as shown by the lactate: 
glucose ratio (Table 1a). Increasing the extracellular glu-
cose concentration to 11 or 22 mmol/L affected neither 
the glucose consumption nor the lactate: glucose ratio 
(Additional file 1: Figure S1 in the online-only data sup-
plement and Table 1a). Furthermore, it did not increase 
the total glucose transport capacity (Fig.  1a) nor the 
expression of GLUT1, the predominant glucose trans-
porter described in vascular cells [13] (Fig. 1b and Addi-
tional file 1: Figure S2).
When cells were activated with IL1β (1–10  ng/mL), 
however, glucose consumption was enhanced in a con-
centration-dependent manner (Fig.  1c). Moreover, at 
each concentration of IL1β, the consumption of glu-
cose was proportional to its extracellular concentration 
(Fig. 1c), although the lactate: glucose ratio was not sig-
nificantly modified (Table  1a). The increased consump-
tion of glucose caused by IL1β was related to increased 
GLUT1 mRNA (by 70.4 ± 16.3 %; P < 0.05; n = 3) and 
a higher expression of GLUT1 (Fig.  1b and Additional 
file 1: Figure S2) that enhanced glucose transport capac-
ity (Fig. 1d). The IL-1 receptor antagonist anakinra (1 µg/
mL) abolished the ability of IL1β to enhance the trans-
port capacity of glucose (3H-deoxyglucose uptake was 
171.6  ±  19.3, 493.3  ±  65.0, and 177.8  ±  4.0  dpm/µg 
protein in control, IL1β and IL1β plus anakinra, respec-
tively, incubated in 5.5 mmol/L glucose; P < 0.05, n = 4). 
Enhancing glucose concentration, however, did not affect 
the effects of IL1β on GLUT1 expression or glucose 
transport capacity (Fig. 1a and 1b, and Additional file 1: 
Figure S2).
Glucose overload is not sufficient to cause cell 
inflammation
We confirmed our previous findings that activation 
of cells with IL1β resulted in cell inflammation [6], 
determined as the activation of NFκB and the expres-
sion of iNOS. This effect was exaggerated in the pres-
ence of high glucose (Fig. 2a, b), through a mechanism 
independent of hyperosmolarity [6]. Because of the 
above, we decided to investigate whether the simple 
increase in the entry of glucose was sufficient to cause 
inflammation.
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In order to achieve this, we first over-expressed GLUT1 
transporters by infecting the cells with a lentiviral vec-
tor containing human GLUT1 cDNA (GLUT1+). Over-
expression of GLUT1 was verified by quantification of 
GLUT1 mRNA levels (Additional file  1: Figure S3A). 
While the glucose transport capacity was increased by 
approximately 50  % in GLUT1+  cells but not in con-
trol cells transduced with an empty vector (EV) (Addi-
tional file  1: Figure S3B), glucose consumption was not 
significantly enhanced when the extracellular glucose 
concentration was increased to 22  mmol/L (Table  1b). 
Moreover, lactate production and the lactate: glucose 
ratio in GLUT1+  and EV cells was similar to those in 
control cells (Table 1b).
In a different set of experiments, we increased glucose 
entry in the cells by inhibiting mitochondrial respiration 
using sodium azide (0.5  mM). This treatment did not 
affect cell survival after 24 h (data not shown), however 
it increased glucose transport (3H-deoxyglucose uptake 
of 171.6 ± 19.3 and 345.3 ± 46.7 dpm/µg protein in con-
trol and plus sodium azide, respectively; P < 0.05, n = 4). 
This was associated with an increase in surface GLUT1 
transporters (Additional file  1: Figure S4), without a 
modification in GLUT1 mRNA levels (98.6 ± 17.0 % vs 
non-treated cells, n =  3). Sodium azide treatment pro-
duced a marked increase in glucose utilization, with-
out changing the lactate: glucose ratio significantly 
(Table 1a).
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Neither the over-expression of GLUT1 nor the glucose 
overload after sodium azide treatment were sufficient to 
induce inflammation (Fig. 2a, b).
IL1β modifies the intracellular metabolic profile of glucose
We next monitored the intracellular utilization of glu-
cose by measuring the generation of 14CO2 from glucose 
labelled in different carbon atoms. The production of 
14CO2 from [6-14C]glucose, which decarboxylates only 
via the tricarboxylic acid cycle, was not modified by incu-
bation in a high concentration of glucose (Fig. 3a). There 
was, however, a significant increase following treatment 
with IL1β, which was similar at both 5.5 and 22 mmol/L 
glucose (Fig.  3a). The activity of the pentose phosphate 
pathway (PPP) was not significantly affected by increas-
ing the concentration of glucose in the medium or by 
incubating cells in 5.5 mmol/L glucose with IL1β (10 ng/
ml); however, a significant enhancement was observed 
when the cells were activated by IL1β in a medium con-
taining 22  mmol/L glucose (Fig.  3b). The protein levels 
of glucose-6-phosphate dehydrogenase (G6PD), as the 
step-limiting enzyme of the PPP, were slightly increased 
after IL1β treatment in 5.5 mmol/L glucose, but markedly 
enhanced in 22 mmol/L glucose (Fig. 3c).
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Over‑activation of NADPH oxidase by IL1β and high 
glucose
NADPH generated by the PPP can be used either to 
regenerate reduced glutathione (GSH) through the action 
of glutathione reductase or as a substrate to fuel NADPH 
oxidase. We found that incubation in 5.5  mmol/L glu-
cose with IL1β increased both total glutathione and 
GSH; however, this effect was abolished in cells incu-
bated in 22 mmol/L glucose (Fig. 3d). In the absence of 
the cytokine, simply enhancing the extracellular concen-
tration of glucose failed to modify the intracellular glu-
tathione profile (Fig. 3d).
Measurements of the NADPH oxidase showed that 
IL1β elicited a concentration-dependent activation of 
this enzyme, which was exaggerated in the presence of 
high glucose (Fig.  4a). NADPH oxidase activity was not 
modified by just enhancing glucose transport capacity 
or following mitochondrial inhibition (Fig. 4b). By using 
the antioxidant and NADPH oxidase inhibitor apoc-
ynin as well as anakinra, we observed that the activation 
of NADPH oxidase via IL-1 receptors was necessary to 
induce inflammation by IL1β and its enhancement by 
high glucose (Figs. 4c, d).
The over‑activation of NADPH oxidase depends on the PPP 
activation
To study the role of the PPP on the activation of NADPH 
oxidase, we used the G6PD pharmacological inhibi-
tor 6-aminonicotinamide (6-ANAM). In cells activated 
with IL1β this compound prevented the activation of 
NADPH oxidase and the resulting inflammation at 5.5 
and 22 mmol/L glucose (Figs. 5a, b, c). To obtain a more 
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selective blockade of G6PD activity, cells were treated 
with G6PD siRNA (Fig.  6a). There was a significant 
increase (P < 0.005) in the basal NADPH oxidase activ-
ity and iNOS expression produced both by scrambled 
or G6PD siRNA, suggesting the experimental procedure 
may originate some unspecific inflammation. Interest-
ingly, however, G6PD silencing specifically blocked the 
over-activation of NADPH oxidase and the enhanced 
iNOS expression induced by high glucose (Figs. 6b, c, d).
High glucose potentiates endothelial dysfunction induced 
by IL1β by a mechanism involving NADPH oxidase and PPP
We first confirmed our previous results [12] demon-
strating that treating isolated segments of rat mesenteric 
microvessels with 2.5  ng/ml produced an impairment 
of the endothelium-dependent relaxations evoked by 
ACh through a mechanism dependent on NADPH oxi-
dase (Fig. 7a; Additional file 1: Figure S5). Moreover, we 
observed that the endothelial dysfunction induced by the 
cytokine was further enhanced when the vascular seg-
ments were pre-incubated in a medium with 22 mmol/L 
glucose (Fig.  7a). The role of the PPP was studied by 
treating the mesenteric microvessels with 6-ANAM; this 
drug did not affect the endothelial dysfunction induced 
by IL1β in normal glucose but prevented the potentiation 
observed in high glucose conditions (Figs. 7b, c).
Discussion
Our results clearly show that the mere elevation of extra-
cellular glucose does not result in increased uptake by 
human vascular smooth muscle. Indeed, non-inflamed 
cells exhibit a glycolytic profile, which is in line with 
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previous findings [14, 15], with no changes observed in 
glucose consumption and lactate generation when the 
extracellular glucose was elevated. The lack of increase 
in glucose consumption with increasing concentrations 
of glucose can be explained by the saturation of its trans-
port; the glucose transporter GLUT1, predominant in 
vascular cells, has a high affinity and low capacity (Km 
of 1–7  mmol/L), operating near its maximal capacity 
at physiological concentrations of glucose [13]. In fact, 
it has been shown before that enhancing the extracel-
lular concentration of glucose may even down-regulate 
GLUT1 activity [16].
However, treating these cells with IL1β increased the 
glucose transport in a concentration-dependent manner. 
This enhanced glucose uptake was associated with newly 
synthesized GLUT1 and increased number of trans-
porters in the cell membrane, similar to what occurs in 
immune cells after inflammatory activation [17]. There 
was, in addition, an increase in both the consumption of 
glucose and the generation of lactate, which was propor-
tional to the concentration of glucose in the extracellular 
medium. Thus, our results also indicate that the cytokine 
is required to achieve extra glucose entry and consump-
tion by the cells when the extracellular concentrations of 
glucose are high.
We confirmed that inflammation induced by IL1β 
was exacerbated in the presence of high concentrations 
of glucose [6]; then, we decided to investigate whether 
increasing intracellular glucose was sufficient to induce 
inflammation. We found that simply over-expressing 
functional GLUT1 did not lead to high glucose consump-
tion or inflammation. This is in contrast to what has 
been shown by others in non-vascular cells with a very 
higher over-expression of GLUT1 [18–20]. Interestingly, 
however, in animals genetically modified to over-express 
GLUT1 in vascular smooth muscle inflammation was 
only observed when vascular damage was superimposed 
[21]. In addition, inhibition of mitochondrial respiration 
by sodium azide resulted in enhanced glucose consump-
tion and lactate production to an even greater degree 
than that observed following activation with IL1β. Inhi-
bition of mitochondrial respiration is known to increase 
glucose transport through the translocation of pre-exist-
ing GLUT1 to the cell membrane [22]). In spite of this, 
no evidence of glucose-dependent inflammation was 
observed. Therefore, the enhancement of glucose con-
sumption and glycolytic metabolism is not sufficient to 
trigger inflammation in vascular cells.
We then investigated whether the stimulation with 
IL1β modified the glucose metabolism and found that 
the glucose metabolized via the tricarboxylic acid cycle 
was only slightly enhanced by the cytokine treatment, 
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Fig. 7 Endothelial dysfunction evoked by IL1β in rat mesenteric 
microvessels. (a) Effect of IL1β (2.5 ng/mL) on the endothelium‑
dependent relaxations induced by acetylcholine (ACh, 0.1 nmol/L 
to 10 µmol/L) in isolated mesenteric arteries from Sprague–Dawley 
(SD) rats incubated with medium containing 5.5 or 22 mmol/L 
glucose. Data are expressed (mean ± SE) as the percentage of 
the previous contraction induced with 1 µmol/L noradrenaline 
(NA), which averaged 9.36 ± 0.77, 9.33 ± 0.58, 9.04 ± 0.83, and 
9.67 ± 0.74 mNewtons, respectively. The number of segments 
used for every curve, which were obtained from 12 animals are in 
parenthesis. *P < 0.05 vs respective control. †P < 0.05 vs respective 
value in 5.5 mmol/L glucose. (b) Effect of 6‑ANAM (2 mmol/L) on the 
endothelium impairment induced by IL1β in rat vascular mesenteric 
segments incubated in 5.5 mmol/L glucose. Data are expressed 
(mean ± SE) as the percentage of the previous contraction induced 
with NA, which averaged 10.67 ± 0.76, 10.10 ± 0.84, 12.10 ± 1.37, 
and 10.83 ± 1.14 mNewtons, respectively. The number of seg‑
ments used for every curve, which were obtained from 5 animals 
are in parenthesis. *P < 0.05 vs control. (c) Effect of 6‑ANAM on the 
endothelium impairment induced by IL1β in rat vascular mesenteric 
segments incubated in 22 mmol/L glucose. Data are expressed 
(mean ± SE) as the percentage of the previous contraction induced 
with NA, which averaged 10.07 ± 0.55, 10.30 ± 0.71, 9.27 ± 1.76, and 
10.87 ± 1.15 mNewtons, respectively. The number of segments used 
for every curve, which were obtained from 5 animals are in parenthe‑
sis. *P < 0.05 vs control. †P < 0.05 vs IL1β
Page 13 of 15Peiró et al. Cardiovasc Diabetol  (2016) 15:82 
independently of the extracellular glucose concentration. 
This further argues against the hypothesis which suggests 
a main role for mitochondria-derived superoxide anions 
in the vascular damage induced by glucose [1]. In fact, the 
major finding of the present study is the demonstration 
that the PPP is the pathway through which high glucose 
exacerbates inflammation in vascular cells. Specifically, 
high glucose concentrations lead to higher expression 
of G6PD and augmented PPP activity in cells activated 
with IL1β, indicating that the cytokine was required for 
the diversion of the excess intracellular glucose through 
this metabolic pathway. Previous results in vascular cells 
suggest that the PPP activity, which is low in basal condi-
tions, can be activated during inflammation [15, 23, 24].
The PPP is a main source for NADPH, which can be 
used as a cofactor of glutathione reductase for the regen-
eration of GSH or as a substrate for NADPH oxidase for 
the release of free radicals. This pro-oxidant enzyme has 
been suggested to play a key role in diabetes-associated 
atherosclerosis [25]. In our cells, treatment with IL1β 
activated NADPH oxidase, which was necessary for the 
induction of inflammation via the production of reac-
tive oxygen species. In parallel, IL1β increased GSH con-
tent, probably as a compensatory mechanism against 
enhanced free radical formation in inflammation [26]. 
In the presence of high glucose and PPP over-activation, 
however, NADPH oxidase activity by IL1β was further 
increased while the protective effect of GSH was dimin-
ished. NADPH oxidase requires higher concentrations of 
NADPH to be active, as the Michaelis constant for this 
enzyme is 5-fold higher than for glutathione reductase 
[27]. Thus, the over-activation of the PPP would favor 
the utilization of NADPH by NADPH oxidase and the 
excess of free radical generation would further contrib-
ute to exhausting GSH. Furthermore, high glucose has 
been suggested to decrease the de novo synthesis of glu-
tathione through the down-regulation of the expression 
of the glutamate-cysteine ligase [26, 28].
Additional evidence supporting the interaction 
between high glucose and IL1β-induced vascular dam-
age, was provided by functional reactivity experiments 
in rat mesenteric microvessels demonstrating that a 
Fig. 8 Effects of high glucose on inflamed human vascular smooth muscle cells. (a and b) Under low or high extracellular glucose and in the 
absence of cytokine activation, the cell regulates the entry of glucose. (c) However, activation with IL1β augments GLUT‑dependent glucose uptake 
①, enhances PPP activity ② and GSH levels ③, and activates NADPH oxidase ④ and pro‑inflammatory signalling ⑤. (d) When the cytokine 
activation coexists with high concentrations of extracellular glucose, the increased glucose entering the cell ① is partially diverted through an 
over‑stimulated PPP ②, resulting in a pro‑oxidant environment ③ that cannot be counterbalanced by a reduced regeneration of GSH ④, leading 
to enhanced inflammation and ultimately to tissue damage ⑤
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high glucose medium also enhanced the impairment of 
endothelium-dependent relaxations evoked the cytokine. 
Moreover, this exacerbated endothelial dysfunction 
was prevented both by NADPH oxidase inhibition or 
PPP blockade. As we have previous data demonstrating 
that the endothelial dysfunction induced by IL1β is due 
to an increased oxidative stress produced by enhanced 
NADPH oxidase activity, which is also occurring in dia-
betes [12], it seems reasonable to conclude that a path-
way linking the over-activation of PPP with the NADPH 
oxidase activity may have a role in several vascular altera-
tions associated to diabetes mellitus.
Although other studies have reported in cardiovascular 
cells a link between the PPP and NADPH oxidase activa-
tion in the context of hyperglycemia and diabetes [29–33], 
our data clearly single out the role of this pathway as 
responsible for the exacerbated inflammation and vascu-
lar dysfunction induced by high glucose. Thus, inhibition 
of G6PD in vascular cells abrogated not only the over-acti-
vation of NADPH oxidase but also the subsequent exac-
erbated inflammation and endothelial dysfunction, which 
may help to explain a number of other experimental and 
clinical observations. It has been known for many years 
that diabetic patients have a decreased tissue concentration 
of GSH [34, 35], while defects in GSH-dependent antioxi-
dant enzymatic activity have been related to diabetes-asso-
ciated atherosclerosis [36]. Moreover, a lower susceptibility 
to cardiovascular disease has been described in patients 
with G6PD deficiency [37, 38], while mice with genetic 
deficiency in G6PD are protected against atherosclerosis 
[39]. From a translational approach, it is likely that anti-
inflammatory treatment, as adjunct to glucose control, will 
prove of benefit for the prevention or treatment of cardio-
vascular complications in diabetes. This has been suggested 
by the recent use of the IL-1 receptor antagonist anakinra 
in an animal model of diabetes [12] as well as by studies in 
patients with anakinra or canakinumab [41].
Conclusions
Our results indicate that over-activation of the PPP is 
a crucial mechanism by which high glucose exacer-
bates vascular cell damage. Activation of the PPP by 
pro-inflammatory cytokines allows excess glucose to 
enter this metabolic route creating a situation in which 
free radical formation exceeds the capacity of the cell to 
regenerate GSH. This pro-oxidant environment increases 
vascular inflammation and as result, induced the vascular 
damage associated to hyperglycaemia (Fig.  8). Further-
more, from a therapeutic point of view, our results indi-
cate the necessity not only to control glycaemia but also 
to reduce inflammation in order to prevent the potential 
harmful effect of high glucose in vascular cells.
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